Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Am-211. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.76 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | PTGIR | P43119 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Am-211 SCHEMBL29433664 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL137919 | 0.94 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL143473 | 0.94 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL152502 | 0.94 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL138312 | 0.94 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL150877 | 0.94 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL139106 | 0.93 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL15021380 | 0.93 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL12900905 | 0.93 | PTGDR2 (0.86) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL178571 | 0.93 | PTGDR2 (0.86) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572785-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-02-21 | — | — | US | claimed |
| US-20160136119-A1 | DP2 ANTAGONIST AND USES THEREOF | BRICKELL BIOTECH, INC. | 2016-05-19 | — | — | US | claimed |
| EP-2257524-B1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | BRICKELL BIOTECH INC (US) | 2016-01-06 | — | — | EP | claimed |
| US-8815917-B2 | DP2 antagonist and uses thereof | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-08-26 | — | — | US | claimed |
| US-8362044-B2 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | claimed |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| EP-2462110-A2 | DP2 ANTAGONIST AND USES THEREOF | Panmira Pharmaceuticals, LLC (US) | 2012-06-13 | — | — | EP | claimed |
| US-20120058123-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120059055-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | claimed |
| US-8067445-B2 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-11-29 | — | — | US | claimed |
| US-20110098352-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | claimed |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | claimed |
| WO-2011017201-A2 | DP2 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | claimed |
| EP-2257524-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009099902-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090197959-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| US-20090197959-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PTGER2, P2RY2, TBXA2R | PTGDR2 5/4885TBXA2R 3/4885PTGDR 13/4885 |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 12/4885PTGDR 1/4885 |
| US-20120058123-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 12/4885PTGDR 1/4885 |
| US-20110098352-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGIR | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
| US-20090197959-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGIR | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | BDKRB2, TRPV2, CYSLTR2 | PTGDR2 14/4885TBXA2R 7/4885PTGDR 29/4885 |
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | PTGER2, PTGES2, PTGDR2 | PTGDR2 3/4885TBXA2R 20/4885PTGDR 9/4885 |
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | DPEP1, TPP1, DPP9 | PTGDR2 1659/4885TBXA2R 1716/4885PTGDR 2146/4885 |
| US-20120059055-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGIR | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
| US-20160136119-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGES2, PTGDR2 | PTGDR2 3/4885TBXA2R 20/4885PTGDR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.